ReviewCommunications biology2026
The Janus face of host LncRNA in viral infections: Defender or collaborator?
Review in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Non-Coding Transcripts From Diversified Members of IgLec Family Protect Antiviral Effectors From Viral miRNA.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Long non-coding RNAs (lncRNAs) are critical context-dependent regulators of viral infection, functioning as double-edged swords in host defense and viral pathogenesis. Accumulating evidence demonstrates that host lncRNAs exert antiviral effects by modulating innate immune responses, regulating host cell survival/apoptosis, or directly targeting viral genomes. Conversely, viruses exploit lncRNA functions to evade immune surveillance, suppress antiviral signaling, and promote viral replication. This review synthesizes current literature to elucidate the molecular mechanisms governing the functional duality of lncRNAs and their dynamic switching between proviral and antiviral roles during infection. Understanding the precise control of this functional switch is crucial for translating lncRNA biology into novel therapeutic strategies. The functional duality of lncRNAs reflects their deep integration into cellular networks. Harnessing their potential demands mechanistic understanding, precision diagnostics, and dynamically responsive interventions. Key lncRNA-pathway interactions offer promising targets for rationally designed RNA-based antivirals against chronic and drug-resistant viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.